ZYBERNO
Stock Report
Updated Aug 31, 2026

ARRIVENT BIOPHARMA, INC. (AVBP)

Healthcare • NASDAQ

$30.17

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
ARRIVENT BIOPHARMA, INC. (AVBP) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-50.3%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-62.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ARRIVENT BIOPHARMA, INC. (AVBP) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:30.17
Market Cap:$1.44B

Valuation Multiples (2)

P/B Ratio:3.92x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.28B

Price Action & Momentum (3)

Momentum Percentile:84 / 100
% of 52-Week High:84.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-46.7%
Reinvestment Rate:-2.3%
Fundamental Growth Rate (g):1.4%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$11.70
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:14.16x
Quick Ratio:14.16x
Cash Ratio:5.56x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:366,329,000.00
Cash And Cash Equivalents:154,682,000.00
Long Term Debt:$33.00K
Net Debt:-$154.33M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$175.94M

Bottom Line Performance (3)

-$163.74M
Income Before Tax:$0.00
Ebitda Ttm:-178,967,000.00

Operating Expenses (5)

Operating Expenses:175,941,000.00
R And D Expense:144,298,000.00
Sga Expense:31,643,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$394.72M
Current Assets:$394.17M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:27,877,000.00
Current Liabilities:27,844,000.00
Long Term Debt:$33.00K
Short Term Debt:$318.00K

Equity & Capital (3)

Equity:$366.84M
Retained Earnings:-$497.85M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:25,309,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:6,665,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$134.47M$0.00

Investment Activities (1)

Investing Cash Flow:$3.58M

Financing Activities (3)

Financing Cash Flow:$54.87M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:54,724,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.53
-$3.53
Earnings Per Share Ttm:-$3.44

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$3.37

Book Value & Capital (2)

Book Value Per Share:$7.71
Cash Per Share:3.25

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-2.3%
Fundamental Growth Rate (g):1.4%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):7.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:AVBP
Company Name:ARRIVENT BIOPHARMA, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:47.61M
Shares Outstanding Basic:47.61M
Shares Outstanding Diluted:47.61M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 17:50:35 UTC
Data Timestamp:2026-08-31T17:50:35.591449
Scroll to Top